Pharmaceutical giant Eli Lilly and Company announced Wednesday that its antibody treatment reduced the incidence of hospitalizations in patients with mild to moderate symptoms of COVID-19 in clinical trials.
The drug, called LY-CoV555, was developed to help block the coronavirus from entering human cells. That resulted in a 72% reduction in the risk of patients requiring hospitalization, said the company.
According to the South China Morning Post, our bodies make antibodies to ward off foreign substances such as viruses. An antibody treatment is not a vaccine and does not provide permanent protection against SARS-CoV-2, the virus that causes COVID-19. Instead, a person who receives antibody protection gets passive immunization, according The History of Vaccines. The protection offered by the antibodies is short-lived but works right away.
Read more at NEWSMAX.